Abstract
BW12C, a potent left-shifting anti-sickling compound in vitro, was administered to normal healthy male Caucasian volunteers. Doses of 2-20 mg kg-1 given by intravenous infusion over 1 h caused a dose-dependent left-shift of the blood-oxygen saturation curve and at the highest dose some 16% of the haemoglobin existed in a high affinity form. Peak left-shift was observed at the end of infusion and decayed thereafter with a mean half-life of approximately 3 h. There were no adverse systemic effects, either clinical, biochemical or haematological, but there was some local irritation at the intravenous infusion site if the infusion was too concentrated. Pharmacokinetic measurements indicated uptake into erythrocytes, low levels in plasma and a volume of distribution not appreciably greater than the blood volume. A pilot radiolabel study indicated extensive metabolism with elimination into the urine.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Beddell C. R., Goodford P. J., Kneen G., White R. D., Wilkinson S., Wootton R. Substituted benzaldehydes designed to increase the oxygen affinity of human haemoglobin and inhibit the sickling of sickle erythrocytes. Br J Pharmacol. 1984 Jun;82(2):397–407. doi: 10.1111/j.1476-5381.1984.tb10775.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Dean J., Schechter A. N. Sickle-cell anemia: molecular and cellular bases of therapeutic approaches (second of three parts). N Engl J Med. 1978 Oct 12;299(15):804–811. doi: 10.1056/NEJM197810122991504. [DOI] [PubMed] [Google Scholar]
- Franklin I. M., Rosemeyer M. A., Huehns E. R. Sickle cell disease: the proportion of liganded haemoglobin needed to prevent crises. Br J Haematol. 1983 Aug;54(4):579–587. doi: 10.1111/j.1365-2141.1983.tb02137.x. [DOI] [PubMed] [Google Scholar]
- Kenny M. W., Stuart J. Preservation of deformability (filterability) of sickle cells by BW12C during progressive deoxygenation. Br J Haematol. 1983 Nov;55(3):465–471. doi: 10.1111/j.1365-2141.1983.tb02161.x. [DOI] [PubMed] [Google Scholar]
- Sunshine H. R., Hofrichter J., Eaton W. A. Requirement for therapeutic inhibition of sickle haemoglobin gelation. Nature. 1978 Sep 21;275(5677):238–240. doi: 10.1038/275238a0. [DOI] [PubMed] [Google Scholar]